May Health Raises $11.7M to Advance its Novel Technology to Treat PCOS-related Infertility
New investor Nexpring Health™ joins existing investors, including Sofinnova, Bpifrance, and Trill Impact
MENLO PARK, Calif.–(BUSINESS WIRE)–May Health, a medical device company dedicated to helping women living with polycystic ovary syndrome (PCOS), today announced that it raised €10 million ($11.7M) with participation from current investors, including Sofinnova Partners, Trill Impact, and Bpifrance, as well as new investor Nexpring Health™. Nexpring Health is a global leader in assisted reproductive technologies (ART) solutions, focused on advancing the future of fertility care. The company will use funds from this raise to drive completion of its pivotal U.S. Investigational Device Exemption (IDE) trial, REBALANCE, and will also support launch planning in Europe for the company’s Anavi™ System, which received CE Mark certification under the European Union’s Medical Device Regulation (EU MDR) in October 2025.
